drugset

Drugs / IGF-1

Follow last change Sep 2017 re-read 3 minutes ago

IGF-1

also known as IGF-I · Increlex (mecasermin [rDNA origin] injection) · Insulin-like growth factor type I · insulin-like growth factor-1 · MyotrophinTM

Protein / enzyme biologic

Developed for: autism spectrum disorder · cystic fibrosis · Duchenne muscular dystrophy · amyotrophic lateral sclerosis
Investigated by: Autism Science Foundation · Charley's Fund · Children's Hospital Medical Center, Cincinnati · Icahn School of Medicine at Mount Sinai · Ipsen · National Institute of General Medical Sciences (NIGMS)
+2 more
· Stony Brook University · The University of Texas Medical Branch, Galveston

Trials 4

today NCT01970345 · Ph 2 NCT01207908 · Ph 1/2 NCT00566241 · Ph 1 NCT00673309 · Ph 2/3

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT00566241	Jun 2008 → Jun 2012	cystic fibrosis	Stony Brook University	Terminated	No outcome recorded Stop: Enrollment
Phase 1/21 trial · 1 missed
Phase 1/2	NCT01207908	Nov 2010 → Oct 2012	Duchenne muscular dystrophy	Children's Hospital Medical Center, Cincinnati	Completed	Missed primary
Phase 21 trial
Phase 2	NCT01970345	May 2014 → Sep 2017	autism spectrum disorder	Icahn School of Medicine at Mount Sinai	Terminated	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT00673309	Jul 2000 → Apr 2011	—	The University of Texas Medical Branch, Galveston	Completed	No outcome recorded
Comparator or background therapy1 trial
Phase 3	NCT00035815 Comparator	Jun 2003 → Aug 2007	amyotrophic lateral sclerosis	Mayo Clinic	Completed	No outcome recorded

Press releases naming this drug 2 releases

Date	Issuer	Release
2005-11-29	Insmed Incorporated	Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency insmed.com ↗
2002-10-07	Insmed Incorporated	Insmed Acquires IGF-1 Regulatory Files for Growth Hormone Insensitivity Syndrome From Pharmacia; Extensive Regulatory Files Expected to Expedite Commercialization of SomatoKine insmed.com ↗

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

Field	Value	Cited text
Known as	IGF-1	“A total of 330 patients from 20 medical centers were randomized to receive 0.05 mg/kg body weight of human recombinant IGF-1 given subcutaneously twice daily or placebo for 2 years.” PMID 19029516 ↗ Nov 2008 4 NCT01970345 ↗ NCT00673309 ↗ NCT01207908 ↗ NCT00566241 ↗
Known as	IGF-I	“The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients.” NCT00035815 ↗
Known as	Increlex (mecasermin [rDNA origin] injection)	“Increlex (mecasermin [rDNA origin] injection)” NCT01207908 ↗
Known as	Insulin-like growth factor type I	“BACKGROUND: Previous human clinical trials of insulin-like growth factor type I (IGF-1) in amyotrophic lateral sclerosis (ALS) have been inconsistent.” PMID 19029516 ↗ Nov 2008
Known as	insulin-like growth factor-1	“The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients.” NCT00035815 ↗
Known as	MyotrophinTM	“The objective of this trial was to determine whether IGF-1 (MyotrophinTM) slows progression of weakness in amyotrophic lateral sclerosis (ALS).” NCT00035815 ↗
Modality	Protein / enzyme biologic	“human recombinant IGF-1” PMID 19029516 ↗ Nov 2008
Route	Subcutaneous	“given subcutaneously twice daily” NCT00035815 ↗